{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:23:19Z","timestamp":1784132599446,"version":"3.55.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA267544"],"award-info":[{"award-number":["R01CA267544"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U54CA268084"],"award-info":[{"award-number":["U54CA268084"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-025-08983-z","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:02:25Z","timestamp":1763557345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Druggable genome CRISPR screening identifies the KEAP1\/NRF2 axis as a mediator of PD-L1 expression"],"prefix":"10.1038","volume":"8","author":[{"given":"Fidan","family":"Seker-Polat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Rogozinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngho","family":"Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2728-5160","authenticated-orcid":false,"given":"Fatih","family":"Abdula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadir","family":"Buyukcelebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Abbaszadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin","family":"Kingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Zahra","family":"Paylakhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-7647","authenticated-orcid":false,"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4740-9594","authenticated-orcid":false,"given":"Mazhar","family":"Adli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"8983_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"8983_CR2","doi-asserted-by":"publisher","first-page":"328rv324","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv324 (2016).","journal-title":"Sci. Transl. Med."},{"key":"8983_CR3","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s10147-016-0959-z","volume":"21","author":"J Hamanishi","year":"2016","unstructured":"Hamanishi, J. et al. PD-1\/PD-L1 blockade in cancer treatment: perspectives and issues. Int. J. Clin. Oncol. 21, 462\u2013473 (2016).","journal-title":"Int. J. Clin. Oncol."},{"key":"8983_CR4","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen, L. & Han, X. Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future.  J. Clin. Investig. 125, 3384\u20133391 (2015).","journal-title":"J. Clin. Investig."},{"key":"8983_CR5","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1182\/blood-2010-01-265975","volume":"116","author":"JJ Park","year":"2010","unstructured":"Park, J. J. et al. B7-H1\/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 116, 1291\u20131298 (2010).","journal-title":"Blood"},{"key":"8983_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","volume":"27","author":"MJ Butte","year":"2007","unstructured":"Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H. & Freeman, G. J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27, 111\u2013122 (2007).","journal-title":"Immunity"},{"key":"8983_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ccell.2019.08.009","volume":"36","author":"MK Callahan","year":"2019","unstructured":"Callahan, M. K. & Wolchok, J. D. Recruit or Reboot? How does anti-PD-1 therapy change tumor-infiltrating lymphocytes? Cancer Cell36, 215\u2013217 (2019).","journal-title":"Cancer Cell"},{"key":"8983_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha, J. H., Chan, L. C., Li, C. W., Hsu, J. L. & Hung, M. C. Mechanisms controlling PD-L1 expression in cancer. Mol. Cell 76, 359\u2013370 (2019).","journal-title":"Mol. Cell"},{"key":"8983_CR9","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1172\/JCI126022","volume":"129","author":"LC Chan","year":"2019","unstructured":"Chan, L. C. et al. IL-6\/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.  J. Clin. Investig. 129, 3324\u20133338 (2019).","journal-title":"J. Clin. Investig."},{"key":"8983_CR10","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","volume":"30","author":"SO Lim","year":"2016","unstructured":"Lim, S. O. et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell 30, 925\u2013939 (2016).","journal-title":"Cancer Cell"},{"key":"8983_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.molcel.2019.04.005","volume":"74","author":"X Tu","year":"2019","unstructured":"Tu, X. et al. PD-L1 (B7-H1) competes with the RNA exosome to regulate the DNA damage response and can be targeted to sensitize to radiation or chemotherapy. Mol. Cell 74, 1215\u20131226.e1214 (2019).","journal-title":"Mol. Cell"},{"key":"8983_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher, A. M., Workman, C. J. & Vignali, D. A. A. Interferon-gamma: teammate or opponent in the tumour microenvironment? Nat. Rev. Immunol. 22, 158\u2013172 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"8983_CR13","doi-asserted-by":"publisher","unstructured":"Finan, C. et al. The druggable genome and support for target identification and validation in drug development. Sci. Transl. Med. 9, https:\/\/doi.org\/10.1126\/scitranslmed.aag1166 (2017).","DOI":"10.1126\/scitranslmed.aag1166"},{"key":"8983_CR14","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1101\/gr.245571.118","volume":"29","author":"HH Jeong","year":"2019","unstructured":"Jeong, H. H., Kim, S. Y., Rousseaux, M. W. C., Zoghbi, H. Y. & Liu, Z. Beta-binomial modeling of CRISPR pooled screen data identifies target genes with greater sensitivity and fewer false negatives. Genome Res. 29, 999\u20131008 (2019).","journal-title":"Genome Res."},{"key":"8983_CR15","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz, A. et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 19, 1189\u20131201 (2017).","journal-title":"Cell Rep."},{"key":"8983_CR16","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun, C., Mezzadra, R. & Schumacher, T. N. Regulation and function of the PD-L1 checkpoint. Immunity 48, 434\u2013452 (2018).","journal-title":"Immunity"},{"key":"8983_CR17","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.2147\/OTT.S105862","volume":"9","author":"X Wang","year":"2016","unstructured":"Wang, X., Teng, F., Kong, L. & Yu, J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 9, 5023\u20135039 (2016).","journal-title":"Onco Targets Ther."},{"key":"8983_CR18","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.3389\/fimmu.2018.02129","volume":"9","author":"AV Bazhin","year":"2018","unstructured":"Bazhin, A. V., von Ahn, K., Fritz, J., Werner, J. & Karakhanova, S. Interferon-alpha up-regulates the expression of PD-L1 molecules on immune cells through STAT3 and p38 signaling. Front. Immunol. 9, 2129 (2018).","journal-title":"Front. Immunol."},{"key":"8983_CR19","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4049\/jimmunol.1800129","volume":"201","author":"W Xiao","year":"2018","unstructured":"Xiao, W., Klement, J. D., Lu, C., Ibrahim, M. L. & Liu, K. IFNAR1 controls autocrine type I IFN regulation of PD-L1 expression in myeloid-derived suppressor cells. J. Immunol. 201, 264\u2013277 (2018).","journal-title":"J. Immunol."},{"key":"8983_CR20","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/ni1255","volume":"6","author":"S Sato","year":"2005","unstructured":"Sato, S. et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat. Immunol. 6, 1087\u20131095 (2005).","journal-title":"Nat. Immunol."},{"key":"8983_CR21","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/35085597","volume":"412","author":"C Wang","year":"2001","unstructured":"Wang, C. et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412, 346\u2013351 (2001).","journal-title":"Nature"},{"key":"8983_CR22","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/ng1248","volume":"35","author":"N Wakabayashi","year":"2003","unstructured":"Wakabayashi, N. et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat. Genet. 35, 238\u2013245 (2003).","journal-title":"Nat. Genet."},{"key":"8983_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1365-2443.2010.01473.x","volume":"16","author":"K Taguchi","year":"2011","unstructured":"Taguchi, K., Motohashi, H. & Yamamoto, M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16, 123\u2013140 (2011).","journal-title":"Genes Cells"},{"key":"8983_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature23643","volume":"549","author":"ML Burr","year":"2017","unstructured":"Burr, M. L. et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 549, 101\u2013105 (2017).","journal-title":"Nature"},{"key":"8983_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature23669","volume":"549","author":"R Mezzadra","year":"2017","unstructured":"Mezzadra, R. et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature 549, 106\u2013110 (2017).","journal-title":"Nature"},{"key":"8983_CR26","doi-asserted-by":"publisher","first-page":"10370","DOI":"10.18632\/aging.103263","volume":"12","author":"JL Yang","year":"2020","unstructured":"Yang, J. L. et al. Keap1-Nrf2 signaling activation by bardoxolone-methyl ameliorates high glucose-induced oxidative injury in human umbilical vein endothelial cells. Aging 12, 10370\u201310380 (2020).","journal-title":"Aging"},{"key":"8983_CR27","doi-asserted-by":"publisher","first-page":"e98896","DOI":"10.1371\/journal.pone.0098896","volume":"9","author":"A Cleasby","year":"2014","unstructured":"Cleasby, A. et al. Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO. PLoS ONE 9, e98896 (2014).","journal-title":"PLoS ONE"},{"key":"8983_CR28","doi-asserted-by":"publisher","unstructured":"Rojas-Rivera, J., Ortiz, A. & Egido, J. Antioxidants in kidney diseases: the impact of bardoxolone methyl. Int. J. Nephrol. 2012, https:\/\/doi.org\/10.1155\/2012\/321714 (2012).","DOI":"10.1155\/2012\/321714"},{"key":"8983_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/1535-7163.MCT-06-0516","volume":"6","author":"MS Yates","year":"2007","unstructured":"Yates, M. S. et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol. Cancer Ther. 6, 154\u2013162 (2007).","journal-title":"Mol. Cancer Ther."},{"key":"8983_CR30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41573-018-0008-x","volume":"18","author":"A Cuadrado","year":"2019","unstructured":"Cuadrado, A. et al. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat. Rev. Drug Discov. 18, 295\u2013317 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"8983_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/1756285614564152","volume":"8","author":"R Bomprezzi","year":"2015","unstructured":"Bomprezzi, R. Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview. Ther. Adv. Neurol. Disord. 8, 20\u201330 (2015).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"8983_CR32","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1111\/febs.15485","volume":"288","author":"S Unni","year":"2021","unstructured":"Unni, S., Deshmukh, P., Krishnappa, G., Kommu, P. & Padmanabhan, B. Structural insights into the multiple binding modes of dimethyl fumarate (DMF) and its analogs to the Kelch domain of Keap1. FEBS J. 288, 1599\u20131613 (2021).","journal-title":"FEBS J."},{"key":"8983_CR33","doi-asserted-by":"publisher","first-page":"19589","DOI":"10.1073\/pnas.0709483104","volume":"104","author":"XJ Wang","year":"2007","unstructured":"Wang, X. J., Hayes, J. D., Henderson, C. J. & Wolf, C. R. Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proc. Natl. Acad. Sci. USA 104, 19589\u201319594 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"8983_CR34","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1038\/s41388-018-0314-0","volume":"37","author":"B Zhu","year":"2018","unstructured":"Zhu, B. et al. Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy. Oncogene 37, 4941\u20134954 (2018).","journal-title":"Oncogene"},{"key":"8983_CR35","doi-asserted-by":"publisher","unstructured":"Zhu, Y. et al. Pharmacological suppression of the OTUD4\/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers. J. Clin. Investig. 134, https:\/\/doi.org\/10.1172\/jci176390 (2024).","DOI":"10.1172\/jci176390"},{"key":"8983_CR36","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7\u201333 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"8983_CR37","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2018.08.033","volume":"155","author":"F Puleo","year":"2018","unstructured":"Puleo, F. et al. Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features. Gastroenterology 155, 1999\u20132013.e1993 (2018).","journal-title":"Gastroenterology"},{"key":"8983_CR38","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/s41590-020-0761-y","volume":"21","author":"J Leinwand","year":"2020","unstructured":"Leinwand, J. & Miller, G. Regulation and modulation of antitumor immunity in pancreatic cancer. Nat. Immunol. 21, 1152\u20131159 (2020).","journal-title":"Nat. Immunol."},{"key":"8983_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 38, 1\u201310 (2020).","journal-title":"J. Clin. Oncol."},{"key":"8983_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","volume":"155","author":"GL Beatty","year":"2018","unstructured":"Beatty, G. L. et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology 155, 29\u201332 (2018).","journal-title":"Gastroenterology"},{"key":"8983_CR41","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/bjc.2015.101","volume":"112","author":"K Abiko","year":"2015","unstructured":"Abiko, K. et al. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br. J. Cancer 112, 1501\u20131509 (2015).","journal-title":"Br. J. Cancer"},{"key":"8983_CR42","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-12-2199","volume":"19","author":"K Abiko","year":"2013","unstructured":"Abiko, K. et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin. Cancer Res. 19, 1363\u20131374 (2013).","journal-title":"Clin. Cancer Res."},{"key":"8983_CR43","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi, J. et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33, 4015\u20134022 (2015).","journal-title":"J. Clin. Oncol."},{"key":"8983_CR44","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ygyno.2018.10.008","volume":"151","author":"E Hinchcliff","year":"2018","unstructured":"Hinchcliff, E. et al. Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. Gynecol. Oncol. 151, 407\u2013413 (2018).","journal-title":"Gynecol. Oncol."},{"key":"8983_CR45","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","volume":"123","author":"DD Twa","year":"2014","unstructured":"Twa, D. D. et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 123, 2062\u20132065 (2014).","journal-title":"Blood"},{"key":"8983_CR46","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nature09754","volume":"471","author":"C Steidl","year":"2011","unstructured":"Steidl, C. et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471, 377\u2013381 (2011).","journal-title":"Nature"},{"key":"8983_CR47","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green, M. R. et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116, 3268\u20133277 (2010).","journal-title":"Blood"},{"key":"8983_CR48","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature18294","volume":"534","author":"K Kataoka","year":"2016","unstructured":"Kataoka, K. et al. Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancers. Nature 534, 402\u2013406 (2016).","journal-title":"Nature"},{"key":"8983_CR49","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey, S. C. et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227\u2013231 (2016).","journal-title":"Science"},{"key":"8983_CR50","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman, M. Z. et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.  J. Exp. Med. 211, 781\u2013790 (2014).","journal-title":"J. Exp. Med."},{"key":"8983_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584626","volume":"11","author":"F Antonangeli","year":"2020","unstructured":"Antonangeli, F. et al. Regulation of PD-L1 expression by NF-kappaB in cancer. Front. Immunol. 11, 584626 (2020).","journal-title":"Front. Immunol."},{"key":"8983_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.112034","volume":"392","author":"X Jing","year":"2020","unstructured":"Jing, X. et al. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer. Exp. Cell Res. 392, 112034 (2020).","journal-title":"Exp. Cell Res."},{"key":"8983_CR53","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1053\/j.gastro.2019.01.252","volume":"156","author":"H Li","year":"2019","unstructured":"Li, H. et al. MET inhibitors promote liver tumor evasion of the immune response by stabilizing PDL1. Gastroenterology 156, 1849\u20131861 (2019).","journal-title":"Gastroenterology"},{"key":"8983_CR54","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature25015","volume":"553","author":"J Zhang","year":"2018","unstructured":"Zhang, J. et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 553, 91\u201395 (2018).","journal-title":"Nature"},{"key":"8983_CR55","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1158\/2326-6066.CIR-21-0754","volume":"9","author":"J Lin","year":"2021","unstructured":"Lin, J. et al. The SETDB1-TRIM28 complex suppresses antitumor immunity. Cancer Immunol. Res. 9, 1413\u20131424 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"8983_CR56","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41588-021-00778-2","volume":"53","author":"E Papalexi","year":"2021","unstructured":"Papalexi, E. et al. Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens. Nat. Genet. 53, 322\u2013331 (2021).","journal-title":"Nat. Genet."},{"key":"8983_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/2056-4538.12390","volume":"10","author":"X Zhang","year":"2024","unstructured":"Zhang, X. et al. Correlation of PD-L1 expression with CD8+ T cells and oxidative stress-related molecules NRF2 and NQO1 in esophageal squamous cell carcinoma. J. Pathol. Clin. Res. 10, e12390 (2024).","journal-title":"J. Pathol. Clin. Res."},{"key":"8983_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06563-3","volume":"15","author":"J Li","year":"2024","unstructured":"Li, J. et al. KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC. Cell Death Dis. 15, 175 (2024).","journal-title":"Cell Death Dis."},{"key":"8983_CR59","doi-asserted-by":"publisher","first-page":"e955","DOI":"10.1634\/theoncologist.2019-0885","volume":"25","author":"X Xu","year":"2020","unstructured":"Xu, X. et al. NFE2L2\/KEAP1 mutations correlate with higher tumor mutational burden value\/PD-L1 expression and potentiate improved clinical outcome with immunotherapy.  Oncologist 25, e955\u2013e963 (2020).","journal-title":"Oncologist"},{"key":"8983_CR60","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1158\/0008-5472.CAN-15-1584","volume":"76","author":"H Satoh","year":"2016","unstructured":"Satoh, H. et al. NRF2 intensifies host defense systems to prevent lung carcinogenesis, but after tumor initiation accelerates malignant cell growth. Cancer Res. 76, 3088\u20133096 (2016).","journal-title":"Cancer Res."},{"key":"8983_CR61","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1158\/0008-5472.CAN-22-3848","volume":"83","author":"JM DeBlasi","year":"2023","unstructured":"DeBlasi, J. M. et al. Distinct Nrf2 signaling thresholds mediate lung tumor initiation and progression. Cancer Res. 83, 1953\u20131967 (2023).","journal-title":"Cancer Res."},{"key":"8983_CR62","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature10189","volume":"475","author":"GM DeNicola","year":"2011","unstructured":"DeNicola, G. M. et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106\u2013109 (2011).","journal-title":"Nature"},{"key":"8983_CR63","doi-asserted-by":"publisher","first-page":"e0135257","DOI":"10.1371\/journal.pone.0135257","volume":"10","author":"BL Probst","year":"2015","unstructured":"Probst, B. L., McCauley, L., Trevino, I., Wigley, W. C. & Ferguson, D. A. Cancer cell growth is differentially affected by constitutive activation of NRF2 by KEAP1 deletion and pharmacological activation of Nrf2 by the synthetic triterpenoid, RTA 405. PLoS ONE 10, e0135257 (2015).","journal-title":"PLoS ONE"},{"key":"8983_CR64","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1016\/j.ymthe.2024.08.019","volume":"32","author":"Y Jo","year":"2024","unstructured":"Jo, Y. et al. Targeting ROS-sensing Nrf2 potentiates anti-tumor immunity of intratumoral CD8(+) T and CAR-T cells. Mol. Ther. 32, 3879\u20133894 (2024).","journal-title":"Mol. Ther."},{"key":"8983_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102904","volume":"67","author":"L Baird","year":"2023","unstructured":"Baird, L. & Yamamoto, M. Immunoediting of KEAP1-NRF2 mutant tumours is required to circumvent NRF2-mediated immune surveillance. Redox Biol. 67, 102904 (2023).","journal-title":"Redox Biol."},{"key":"8983_CR66","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.arbres.2024.06.021","volume":"60","author":"SV Ramisetti","year":"2024","unstructured":"Ramisetti, S. V. et al. NRF2 signaling pathway in chemo\/radio\/immuno-therapy resistance of lung cancer: looking beyond the tip of the iceberg. Arch. Bronconeumol. 60, S59\u2013S66 (2024).","journal-title":"Arch. Bronconeumol."},{"key":"8983_CR67","doi-asserted-by":"crossref","unstructured":"Zavitsanou, A. M. et al. KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance. Cell Rep. 42, 113295 (2023).","DOI":"10.1016\/j.celrep.2023.113295"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08983-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08983-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08983-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T14:04:17Z","timestamp":1763561057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-08983-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8983"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-08983-z","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1610"}}